UWCCC Cancer Prevention and Control (CPC) Program Summary Co-Leaders: Hasan Mukhtar and Amy Trentham-Dietz PROJECT SUMMARY/ABSTRACT The Cancer Prevention & Control (CPC) Program spans basic, clinical, and population science to identify effective approaches to reduce the burden of cancer for patients, their families, and communities through improved prevention, early detection, and survival. In support of this overarching goal, the CPC program has defined three thematic aims. Theme 1: Identify promising chemopreventive targets and agents to test in clinical trials. Members build on a comprehensive integrated understanding of agents that decrease the incidence of cancer or its progression to clinically significant disease through drug development and clinical testing. Theme 2: Identify and implement effective approaches to reduce tobacco-related cancers. Members conduct intervention studies of innovative tobacco cessation approaches and lead observational cohort studies of real-world smoking patterns. Research focuses on underserved and minority populations since these are the same groups among whom the prevalence of smoking is greatest. Theme 3: Identify new strategies to improve the delivery of cancer care. Members identify effective approaches for delivering cancer screening and diagnostic tests and cancer therapies. CPC members are using innovative simulation modeling, bioinformatics, and multidisciplinary teams to improve the early detection of cancer; to leverage insights obtained through analysis of large databases to test approaches for improving access to guideline- concordant clinical care; and to incorporate patient-centered outcomes. CPC projects directly address the priorities present in the UWCCC catchment area and support reduction in cancer health disparities. The CPC Program has 33 members in 14 departments and 4 schools/colleges. Since 2012, CPC members have published 776 peer-reviewed manuscripts (25% intra-programmatic, 22% inter-programmatic). PIs were responsible for $11.1 million (direct costs) overall in peer-reviewed grant funding, with 60%, $6.7 million from NCI. Recent programmatic changes include new leadership, Dr. H. Mukhtar and Dr. A. Trentham-Dietz, and increased focus on interventions to reduce cancer and cancer risks in our communities. The CPC Program supports inter- and intra-programmatic interaction through pilot grants, seminars and retreats, a strong mentorship program, and collaborative working groups. Guided by strategic planning, priorities for the CPC program over the next 5 years include emphasizing cross-aim collaborations, building on existing momentum in health services research, and translational disparities research addressing needs in the UWCCC catchment area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014520-44
Application #
9490024
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-05-30
Budget End
2019-03-31
Support Year
44
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Liu, Ting; Shi, Changzheng; Duan, Linqi et al. (2018) A highly hemocompatible erythrocyte membrane-coated ultrasmall selenium nanosystem for simultaneous cancer radiosensitization and precise antiangiogenesis. J Mater Chem B 6:4756-4764
Zhan, Yonghua; Ehlerding, Emily B; Shi, Sixiang et al. (2018) Intrinsically Zirconium-89-Labeled Manganese Oxide Nanoparticles for In Vivo Dual-Modality Positron Emission Tomography and Magnetic Resonance Imaging. J Biomed Nanotechnol 14:900-909
Schumacher, Jessica R; Neuman, Heather B; Chang, George J et al. (2018) A National Study of the Use of Asymptomatic Systemic Imaging for Surveillance Following Breast Cancer Treatment (AFT-01). Ann Surg Oncol 25:2587-2595
Turk, Anita A; Wisinski, Kari B (2018) PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. Cancer 124:2498-2506
Fricke, Stephanie L; Payne, Susan N; Favreau, Peter F et al. (2018) MTORC1/2 inhibition as a therapeutic strategy for PIK3CA mutant cancers. Mol Cancer Ther :
Feld, Shara I; Fan, Jun; Yuan, Ming et al. (2018) Utility of Genetic Testing in Addition to Mammography for Determining Risk of Breast Cancer Depends on Patient Age. AMIA Jt Summits Transl Sci Proc 2017:81-90
Bloom, Debra D; Reshetylo, Sofiya; Nytes, Cassandra et al. (2018) Blockade of BAFF Receptor BR3 on T Cells Enhances Their Activation and Cytotoxicity. J Immunother 41:213-223
Wei, Weijun; Jiang, Dawei; Ehlerding, Emily B et al. (2018) Noninvasive PET Imaging of T cells. Trends Cancer 4:359-373
Robins, H Ian; Nguyen, HuyTram N; Field, Aaron et al. (2018) Molecular Evolution of a Glioblastoma Controlled With Tumor Treating Fields and Concomitant Temozolomide. Front Oncol 8:451
Esbona, Karla; Yi, Yanyao; Saha, Sandeep et al. (2018) The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma Patients. Am J Pathol 188:559-573

Showing the most recent 10 out of 1528 publications